Difference between revisions of "Profiles"

From QIBA Wiki
Jump to: navigation, search
 
(166 intermediate revisions by 4 users not shown)
Line 1: Line 1:
 
__NOTOC__
 
__NOTOC__
Profiles published here have completed one of the '''[[QIBA Profile Stages]]''' of development and been approved by their [[Committees|Biomarker Committee]].
+
Profiles published here have completed one of the '''[[QIBA Profile Stages]]''' of development and been approved by their [[Committees|Biomarker Committee]]
 +
 
 +
Profiles '''[[How to use QIBA Profiles|may be of use]]''' at any Stage.
  
 
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Technically Confirmed Profiles===
 
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Technically Confirmed Profiles===
 +
 +
* [[Media:QIBA_CTVol_TumorVolumeChangeProfile_TechConfirmed-20180622a.pdf|CT Tumor Volume Change for Advanced Disease (CTV-AD) 2018-06-22]]
 +
:* Conformance Checklists (refer to Appendix C in the Profile document - pg 42)
 +
:* Assessment Procedures (refer to Section 4 in the Profile document - pg 30)
 +
 
* [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]]
 
* [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]]
:* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 Dec-2014]]
+
:* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]]
 +
 
 +
* [[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.11.18-clean-3.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]]
 +
 
  
 
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
 
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
*[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v1.1 2017-06-26]]  
+
 
 +
*[[Media:QIBA_DSC-MRI_Stage2-Consensus_Profile.pdf| MR Dynamic Contrast Susceptibility (DSC) 2020-10-22]]
 +
 
 +
*[[Media:QIBA_DWIProfile_Consensus_Dec2019_Final.pdf| MR Diffusion-Weighted Imaging (DWI) 2019-12-20]]
 +
 
 +
*[[Media:QIBA_AmyloidPET_20June2018_consensus.pdf | PET F-18 for Amyloid 2018-06-20]]
 +
 
 +
*[[Media:MRE-QIBA_Profile-2019-06-06-CONSENSUS-maintenance.pdf | MR Elastography of the Liver 2019-06-06]]
 +
 
 +
*[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Ioflupane for Neurodegenerative Disease v1.1, 2017-06-26]]
 +
 
 +
*[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf | SPECT Ioflupane for Neurodegenerative Disease v2.0, 2019-10-15]]
 +
 
 
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]]
 
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]]
  
* [[Media:QIBA_CTVol_TumorVolumeChangeProfile_Consensus-20161121b.pdf| CT Tumor Volumetry for Advanced Disease 2016-11-21b]]  
+
*[[Media:DCE-MRI Quantification Profile v1.0.pdf|MR DCE Quantification v1.0 2012-08-08]]
:* [[Media:QIBA_CVol_TumorVolumeChangeChecklist-20161205_-_Field_Test_version_1.0.docx| Checklist - CT Tumor Volumetry for Advanced Disease]]
+
 
 +
*[[Media:QIBA_CTA_Profile_as_of_2020-Mar-10.pdf| CTA Atherosclerosis 2020-03-10]]
 +
 
 +
*[[Media:QIBA_SPECT_99mTC_Profile_10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]]
  
* [[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.02.11.docx|QIBA Small Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening Profile 2018.02.11]]
 
 
*[[Media:DCE-MRI Quantification Profile v1.0.pdf|QIBA DCE-MRI Quantification Profile, v 1.0 2012-08-08]]
 
  
 
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
 
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
  
Submit comments using the online form: ''' http://tinyurl.com/QIBA-Public-Comment-Form '''
+
'''Please submit comments using the '''[http://tinyurl.com/QIBA-Public-Comment-Form '''online form''']'''
<br \><font size="2" color="FireBrick">(Note: each form accommodates 10 comments; submit additional forms as necessary)</font>
+
  
* ''There are currently no Profiles open for Public Comment''  
+
*[[Media:QIBA_Profile_MSK-Cartilage-Stage1_Profile.pdf|MR MSK cartilage for joint disease 2020-05-18]] (<font color=##00cc00>'''Open for comment: June 26, 2020 - Thursday, October 29, 2020 [extended]'''</font>)
  
Public Comment closed for the following Profiles (comment resolution is currently underway):
+
*[[Media:QIBA_US_SWS_Profile_10.21.19.pdf|US Shear Wave Speed for Liver Fibrosis 2019-10-21]] ('''closed''' on December 18, 2019)
*[[Media:QIBA_fMRI_Profile_1_PC-rev1.pdf| QIBA fMRI Profile 2017-06-19]] (''Closed on December 31, 2017'')
+
*[[Media:QIBA_AmyloidPET_15June2017.pdf| QIBA PET Amyloid Profile 2017-06-15]] (''Closed on September 15, 2017'')
+
*[[Media:Draft-MRE-QIBAProfile-2017-07-28_clean.pdf| QIBA MRE Profile 2017-08-15]] (''Closed on September 15, 2017'')
+
*[[Media:QIBADWIProfilev1.45_20170427_v5_accepted_linenumbers.pdf| DWI Profile 2017-04-27]] (''Closed on August 25, 2017'')
+
  
==Format for Citing Profiles==
+
:*[[Media:SWS Checklists-Appendix E.xlsx|Appendix E: SWS Checklists, 2019-10-21]] ('''closed''' on December 18, 2019)
 +
 
 +
*[[Media:QIBA_CT_Lung_Density_Profile_090319-clean.pdf | CT Lung Density 2019-09-03]] (Contains Conformance Checklist, Appendix B) ('''closed''' on October 16, 2019)
 +
 
 +
:*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Appendix E:CT Lung Density Protocols 2019-06-26]] ('''closed''' on October 16, 2019)
 +
 
 +
*[[Media:QIBA_fMRI_Profile_1_PC-rev1.pdf| fMRI for Sensorimotor Mapping 2017-06-19]] ('''closed''' on December 31, 2017)
 +
 
 +
 
 +
'''[[Comment Resolutions]]''' <font color=black>are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''.<font>
 +
 
 +
 
 +
====Format for Citing Profiles====
 
Cite QIBA Profile documents as:
 
Cite QIBA Profile documents as:
  
: Specific QIBA Biomarker Committee. * Specific Profile Title, * Quantitative Imaging Biomarkers Alliance. * Version. * Profile Stage. * QIBA, * Date. * Available from: URL
+
: ''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Version. Profile Stage''. ''Date''. Available from: ''URL''
  
 
Example:
 
Example:
  
: QIBA SPECT Biomarker Committee. Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases, Quantitative Imaging Biomarkers Alliance. Version 1.1.  Profile Stage: Consensus. QIBA, June 30, 2017. Available from: http://qibawiki.rsna.org/index.php/Profiles
+
: QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles
  
==Statements of Endorsement==
+
====Statements of Endorsement====
 
*[[Industry]]
 
*[[Industry]]
 
*[[Clinical Sites]]
 
*[[Clinical Sites]]
 
*[[Additional letters of support can be found here]]
 
*[[Additional letters of support can be found here]]
  
 
+
====See Also====
==See Also==
+
 
*[[How to use QIBA Profiles]]
 
*[[How to use QIBA Profiles]]
 
*[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage.
 
*[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage.

Latest revision as of 18:56, 22 October 2020

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Profiles may be of use at any Stage.

Stage 3: Technically Confirmed Profiles

  • Conformance Checklists (refer to Appendix C in the Profile document - pg 42)
  • Assessment Procedures (refer to Section 4 in the Profile document - pg 30)


Stage 2: Consensus Profiles


Stage 1: Public Comment Profiles

Please submit comments using the online form


Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.


Format for Citing Profiles

Cite QIBA Profile documents as:

Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Version. Profile Stage. Date. Available from: URL

Example:

QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles

Statements of Endorsement

See Also